Atlas Trials

A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Clinical trial NCT04885712 · COMPLETED

Trial details

NCT number
NCT04885712
Sponsor
Boryung Pharmaceutical Co., Ltd
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Type2 Diabetes
Start date
2021-05-28
Primary completion
2022-09-19
Enrollment
378

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.